The first evidence of the medium-term to long-term safety and tolerability of transplanting human embryonic stem cells (hESCs) in humans has been revealed by scientists. hESC transplants used to treat severe vision loss in 18 patients with different forms of macular degeneration appeared safe up to 3 years post-transplant, and the technology restored some sight in more than half of the patients.

Source: First report of long-term safety of human embryonic stem cells to treat human disease


David Cottle

UBB Owner & Administrator